Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19

References 60

1. 1.

   Horby P, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.

   Not in our library10.1056/nejmoa2021436 (opens in a new tab)

2. 2.

   Beigel JH, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020.

   Not in our library10.1056/nejmoa2007764 (opens in a new tab)

3. 3.

   Kalil AC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine. 2020.

   Not in our library10.1056/nejmoa2031994 (opens in a new tab)

4. 4.

   Nelson MR, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856-860.

   Not in our library10.1038/ng.3314 (opens in a new tab)

5. 5.

   Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.

   Not in our library10.1056/nejmoa054013 (opens in a new tab)

6. 6.

   Lopalco L. CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses. 2010;2:574-600.

   Not in our library10.3390/v2020574 (opens in a new tab)

7. 7.

   Finan C, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9.

   Not in our library10.1126/scitranslmed.aag1166 (opens in a new tab)

8. 8.
   The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis · 2012

   No notice
9. 9.
   The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic · 2020

   No notice
10. 10.

    Gaziano JM, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223.

    Not in our library10.1016/j.jclinepi.2015.09.016 (opens in a new tab)

11. 11.
    Understanding the Assumptions Underlying Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related Tools · 2018

    No notice
12. 12.

    The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580-585.

    Not in our library10.1038/ng.2653 (opens in a new tab)

13. 13.

    Sun BB, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558:73-79.

    Not in our library10.1038/s41586-018-0175-2 (opens in a new tab)

14. 14.
    Genetic architecture of host proteins involved in SARS-CoV-2 infection · 2020

    Corrected
15. 15.

    Borden EC, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6:975-990.

    Not in our library10.1038/nrd2422 (opens in a new tab)

16. 16.

    Emilsson V, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361:769-773.

    Not in our library10.1126/science.aaq1327 (opens in a new tab)

17. 17.
    PhenoScanner: a database of human genotype–phenotype associations · 2016

    No notice
18. 18.

    von Marschall Z, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-448.

    Not in our library10.1093/jnci/95.6.437 (opens in a new tab)

19. 19.

    Jia H, et al. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res. 2018;163:105-116.

    Not in our library10.1016/j.thromres.2018.01.039 (opens in a new tab)

20. 20.

    Casassus P, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.

    Not in our library10.1046/j.1365-2141.2002.03944.x (opens in a new tab)

21. 21.

    Swanson SA, Tiemeier H, Ikram MA, Hernán MA. Nature as a Trialist?: Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials. Epidemiology. 2017;28:653-659.

    Not in our library10.1097/ede.0000000000000699 (opens in a new tab)

22. 22.

    Nelson CP, et al. Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. Circulation. 2020;142:1117-1119.

    Not in our library10.1161/circulationaha.120.049007 (opens in a new tab)

23. 23.
    Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses · 2020

    Corrected
24. 24.

    Hemnes AR, et al. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51.

    Not in our library10.1183/13993003.02638-2017 (opens in a new tab)

25. 25.

    Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J Mol Med (Berl). 2006;84:814-820.

    Not in our library10.1007/s00109-006-0094-9 (opens in a new tab)

26. 26.

    Monteil V, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181:905-913.

    Not in our library10.1016/j.cell.2020.04.004 (opens in a new tab)

27. 27.

    Monteil V, et al. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med. 2020;13:e13426.

    Not in our library10.15252/emmm.202013426 (opens in a new tab)

28. 28.

    Zoufaly A, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020.

    Not in our library10.1016/s2213-2600(20)30418-5 (opens in a new tab)

29. 29.

    Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment forPatients With COVID-19.

    Not in our library

30. 30.

    Onabajo OO, et al. Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nat Genet. 2020;52:1283-1293.

    Not in our library10.1038/s41588-020-00731-9 (opens in a new tab)

31. 31.

    Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036-1045.

    Not in our library10.1016/j.cell.2020.04.026 (opens in a new tab)

32. 32.

    Chu H, et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. Clin Infect Dis. 2020;71:1400-1409.

    Not in our library10.1093/cid/ciaa410 (opens in a new tab)

33. 33.
    Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients · 2020

    No notice
34. 34.

    Bastard P, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020.

    Not in our library10.1126/science.abd4585 (opens in a new tab)

35. 35.

    Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020.

    Not in our library10.1126/science.abd4570 (opens in a new tab)

36. 36.

    van der Made CI, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19. Jama. 2020;324:1-11.

    Not in our library10.1001/jama.2020.13719 (opens in a new tab)

37. 37.

    Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020.

    Not in our library10.1038/s41586-020-03065-y (opens in a new tab)

38. 38.

    Lokugamage KG, et al. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. Journal of Virology. 2020;94:e01410-01420.

    Not in our library10.1128/jvi.01410-20 (opens in a new tab)

39. 39.

    Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811.

    Not in our library10.1016/j.antiviral.2020.104811 (opens in a new tab)

40. 40.

    Clementi N, et al. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection. J Infect Dis. 2020;222:722-725.

    Not in our library10.1093/infdis/jiaa350 (opens in a new tab)

41. 41.

    Dinnon KH, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560-566.

    Not in our library10.1038/s41586-020-2708-8 (opens in a new tab)

42. 42.

    Hung IF, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695-1704.

    Not in our library10.1016/s0140-6736(20)31042-4 (opens in a new tab)

43. 43.

    Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. New England Journal of Medicine. 2020.

    Not in our library10.1056/nejmoa2023184 (opens in a new tab)

44. 44.

    NIAID Stops COVID-19 Trial Enrollment Over Adverse Events. 2020.

    Not in our library

45. 45.

    Liu D, et al. Mendelian randomization analysis identified genes pleiotropically associated with the risk and prognosis of COVID-19. J Infect. 2020.

    Not in our library10.1016/j.jinf.2020.11.031 (opens in a new tab)

46. 46.

    Xiao F, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158:1831-1833.

    Not in our library10.1053/j.gastro.2020.02.055 (opens in a new tab)

47. 47.

    Mao L, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683-690.

    Not in our library10.1001/jamaneurol.2020.1127 (opens in a new tab)

48. 48.

    Song E, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218.

    Not in our library10.1084/jem.20202135 (opens in a new tab)

49. 49.

    Puelles VG, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020;383:590-592.

    Not in our library10.1056/nejmc2011400 (opens in a new tab)

50. 50.
    ChEMBL: towards direct deposition of bioassay data · 2018

    No notice
51. 51.

    Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28:1353-1358.

    Not in our library10.1093/bioinformatics/bts163 (opens in a new tab)

52. 52.

    Rohloff JC, et al. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids. 2014;3:e201.

    Not in our library10.1038/mtna.2014.49 (opens in a new tab)

53. 53.
    Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery · 2010

    No notice
54. 54.

    Chapman AB, et al. A Natural Language Processing System for National COVID-19 Surveillance in the US Department of Veterans Affairs. 2020.

    Not in our library

55. 55.

    Hunter-Zinck H, et al. Genotyping Array Design and Data Quality Control in the Million Veteran Program. Am J Hum Genet. 2020;106:535-548.

    Not in our library10.1016/j.ajhg.2020.03.004 (opens in a new tab)

56. 56.

    Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190-2191.

    Not in our library10.1093/bioinformatics/btq340 (opens in a new tab)

57. 57.

    Giambartolomei C, et al. A Bayesian framework for multiple trait colocalization from summary association statistics. Bioinformatics. 2018;34:2538-2545.

    Not in our library10.1093/bioinformatics/bty147 (opens in a new tab)

58. 58.

    Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011;39:e102.

    Not in our library10.1093/nar/gkr424 (opens in a new tab)

59. 59.

    Olink Target 96 & Target 48 panels for protein biomarker discovery.

    Not in our library

60. 60.

    Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284-287.

    Not in our library10.1089/omi.2011.0118 (opens in a new tab)

Cited by papers we hold 4

• The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods · 2023
  No notice
• Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review · 2022
  Not checked
• FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 · 2022
  No notice
• Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study · 2021
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.